BioMarin Pharmaceutical Inc. (BMRN)
-NasdaqGS 65.76 
0.21(0.32%) 4:00PM EDT|After Hours
:
65.76 0.00 (0.00%) 4:27PM EDT
| Prev Close: | 65.55 |
|---|
| Open: | 64.11 |
|---|
| Bid: | 64.78 x 100 |
|---|
| Ask: | 68.99 x 100 |
|---|
| 1y Target Est: | 69.84 |
|---|
| Beta: | 0.76 |
|---|
| Next Earnings Date: | 29-Jul-13 |
|---|
| Day's Range: | 63.10 - 66.40 |
|---|
| 52wk Range: | 34.30 - 71.56 |
|---|
| Volume: | 962,127 |
|---|
| Avg Vol (3m): | 1,322,810 |
|---|
| Market Cap: | 9.14B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.05 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- BioMarin Gains on Prospects for Experimental Cancer Drugat Bloomberg(Wed May 22)
- BioMarin Pharmaceutical Inc. Presents at UBS Global Healthcare Conference, May-21-2013 09:00 AMat Seeking Alpha(Tue May 21)
- Cramer: Buy BioMarin Pharma, Bristol-Myers Squibb, Asbury Automotive, But Sell These 2 Stocksat Wall St. Cheat Sheet(Tue May 21)
- Cramer's Watch List Ahead of Big Cancer Conferenceat CNBC(Mon May 20)
- [video] The War Against Cancerat CNBC(Mon May 20)
- Catalyst Pharmaceutical's CPP-115 May Be Big Pipeline In Just One Little Pillat Seeking Alpha(Mon May 20)
- BioMarin Pharmaceutical Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswire(Mon May 20)
- BioMarin Announces BMN-673 Data in Breast and Ovarian Cancers to be Released at ASCOGlobeNewswire(Thu May 16)
- Biomarin Stock Falls On Unusually High Volume (BMRN)at TheStreet(Thu May 16)
- A Fundamental, Bottom-Up Approach to Investing in Health Care: Portfolio Manager Finny Kuruvilla Discusses His Strategies with The Wall Street TranscriptWall Street Transcript(Thu May 16)
- Celgene, Gilead lower after new data published at ASCOat theflyonthewall.com(Thu May 16)
- 1 Biotech, 1 Financial And 1 Grocery Store With Recent Intensive Insider Sellingat Seeking Alpha(Thu May 16)
- BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to aEDGAR Online(Thu May 16)
- BioMarin abstract showed impressive anti-tumor activity, says Leerinktheflyonthewall.com(Thu May 16)
- 10 ASCO '13 Abstracts You Can Read Right Nowat TheStreet(Wed May 15)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 17.80 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -1.30 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.29 |
|---|
| Mean Recommendation*: | 1.8 |
|---|
| PEG Ratio (5 yr expected): | -1.47 |
|---|
Business Summary
BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally.
View More